ALX Oncology Holdings Inc
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California. Its pipeline is centered on evorpacept (ALX148), a CD47 blocker designed to enhance macrophage-mediated tumor cell clearance while aiming to avoid hematologic toxicities seen with other CD47 approaches. The company is also advancing ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) built from an in-house linker-payload platform, which entered first-in-human Phase 1 dosing in 2025. ALX Oncology has no products approved for marketing and has not generated revenue from product sales, with operations focused on R&D, clinical trials, and manufacturing scale-up for clinical supply.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical development of evorpacept across Phase 1/2 studies, including combination regimens with targeted antibodies and chemotherapy.
First-in-human clinical development of an EGFR-targeted ADC using an in-house antibody and proprietary linker-payload design.
Earlier-stage programs including partnered assets such as ALTA-002 (TRAAC) combining a SIRPα antibody with a TLR9 agonist.
R&D and CMC capabilities supporting antibody engineering, linker-payload development, and clinical supply manufacturing scale-up.
Customers
ALX Oncology is not yet commercial and therefore does not have traditional product customers; its near-term "customers" are clinical trial stakeholders and research partners that enable development. Clinical trial sites (academic medical centers and hospitals) and principal investigators administer investigational therapies under protocols, while patients enroll to access experimental treatments. The company also interacts with regulators (e.g., FDA) through IND submissions and trial oversight, which shapes development timelines and required evidence. If products are approved, the commercial customer chain would include oncologists and hospitals as prescribers/providers, specialty distributors, and third-party payors that determine reimbursement and access.
Administer evorpacept and ALX2004 under protocols; critical for enrollment, safety monitoring, and data generation.
Academic institutions sponsor studies (e.g., UC San Diego) to explore new combinations/indications that can expand clinical evidence.
Oncologists and infusion centers would adopt therapies based on efficacy/safety and guideline placement if approvals are obtained.
Public and private payors would influence access via coverage, prior authorization, and rebate/price reporting requirements post-approval.
Strategy
The company’s strategy is to advance evorpacept as a next-generation CD47 checkpoint inhibitor positioned for combination use with established anti-cancer antibodies and chemotherapy, aiming to become a backbone therapy in immuno-oncology. A second pillar is building an ADC franchise, starting with ALX2004, leveraging an in-house linker-payload platform to create differentiated EGFR-targeted constructs. ALX Oncology also uses collaborations to broaden its pipeline, exemplified by the Tallac Therapeutics partnership on ALTA-002. Execution priorities include progressing clinical trials, achieving enrollment and readouts, and securing reliable third-party manufacturing for clinical supply and eventual commercial scale if approvals are obtained.
Clinical efficacy and safety data in defined tumor settings drive partnering, pivotal trial design, and eventual approval prospects.
A differentiated ADC platform can create multiple follow-on candidates and diversify dependence on a single asset.
Partnered programs can broaden immuno-oncology approaches while sharing scientific and development risk.
Geography
ALX Oncology is headquartered in South San Francisco, California and operates primarily through U.S.-based clinical development and regulatory activities. The company’s disclosed regulatory milestones in the excerpts are U.S.-centric, including FDA IND filings and clearances for ALX2004 and ALTA-002. Clinical trials are multi-center and may include sites beyond the U.S., but the provided excerpts do not quantify international footprint or revenue by geography. Because the company has no product sales, geographic exposure is driven more by where trials are conducted and where third-party manufacturers and service providers operate than by commercial demand patterns.
Risks
ALX Oncology faces binary clinical development risk because its value is concentrated in investigational assets, particularly evorpacept, which has not completed a pivotal trial. The company expects continued losses and requires substantial additional capital, creating financing and dilution risk if markets are unfavorable. Competitive risk is high in immuno-oncology and ADCs, where new approvals can shift standards of care and undermine trial relevance or enrollment. Operationally, the company relies on third parties (CMOs/CROs) for manufacturing and trial execution, and disruptions at agencies such as the FDA can delay reviews and development timelines. If products reach market, compliance risk increases due to U.S. healthcare laws (Anti-Kickback, False Claims, Sunshine Act) and distribution, pricing, and rebate program requirements.
- Substantial dependence on evorpacept (ALX148) clinical successImpact: CriticalLikelihood: High
The company is substantially dependent on its lead candidate, which remains in clinical development and has not completed a pivotal trial.
Exposure: Pipeline concentration and binary trial outcomes
- Ongoing losses and need to raise additional capitalImpact: HighLikelihood: High
The company has incurred significant net losses, expects continued losses, and will require substantial additional capital that may not be available on favorable terms.
Exposure: Financing/dilution and potential program curtailment
- Competitive displacement and changing standard of careImpact: HighLikelihood: Low
Newly approved therapeutics in immuno-oncology could change treatment paradigms, negatively impacting trial design and prospects for evorpacept and ALX2004.
Exposure: Clinical differentiation and enrollment feasibility
- Regulatory and agency operational disruptionsImpact: MediumLikelihood: Medium
Disruptions at the FDA or other agencies could hinder timely review and approval activities on which development depends.
Exposure: Development timelines and approval uncertainty
Accounting
Judgemental itemsManagement estimates period-end accruals based on trial status and vendor services; differences can shift R&D expense across periods.
Impact: Affects reported R&D expense, accrued liabilities, and quarterly comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Janux Therapeutics, Inc.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
LadRx Corp
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Enliven Therapeutics, Inc.
ELVN · Pharmaceutical Preparations
Last updated: 24/09/2026